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INTRODUCTION
Achieving the appropriate balance of clearance and metabolic stability along with potency and permeability is an integral part of drug discovery efforts and multiparametric lead optimization.
The optimization of metabolic stability is largely focused on the CYP and UDPglucuronosyltransferase (UGT) mediated pathways, since these routes represent the vast majority of clearance pathways for drugs (Guengerich et al., 2005; Rowland et al., 2013) . The role of physicochemical properties on the propensity for clearance by these enzymes is well recognized, as is the importance of physicochemistry in overall hit and lead candidate quality (Gleeson, 2008) . With medicinal chemistry efforts driving towards compounds with low CYP and UGT turnover, recent years have seen a sharp rise in the reported involvement of some of the other, perhaps lesser studied, drug metabolizing enzymes such as aldehyde oxidase (Pryde et al., 2010;  D M D # 6 4 0 1 4 5 aminosalicylic acid (Kawamura et al., 2005; Minchin et al., 1992; Sim et al., 2014) . However, aliphatic amines have not generally been reported to be human NAT1 or NAT2 substrates.
EPZ011652 is a relatively unselective protein arginine N-methyltransferase (PRMT) 1, 6 and 8
inhibitor that was the starting point for a PRMT6 lead optimization effort (Mitchell et al., 2015) .
PRMT6 is a member of the PRMT family which comprises 45 enzymes that are known or presumed to catalyze protein arginine N-methylation reactions on histones and other proteins.
Site-specific histone methylation is critical for chromatin-mediated regulation of gene transcription, and is often genetically altered in human cancers (Copeland, 2013) . PRMT6
overexpression has been reported in several cancer types including melanoma (Limm et al., 2013 ) and bladder, lung and prostate carcinoma (Yoshimatsu et al., 2011; Vieira et al., 2014) suggesting that inhibition of PRMT6 may have therapeutic utility and supporting development of small molecule inhibitors.
During the course of lead optimization, a putative N-acetyl metabolite (M1) of EPZ011652 was observed in in vivo and in vitro samples. The aim of this study was to elucidate the structure of this metabolite and characterize the kinetics and enzymology of this reaction, since the Nacetylation of aliphatic amines represents an unusual biotransformation and has not been widely ethyl}acetamide) were synthesized by Epizyme (Cambridge, MA; Mitchell et al, 2015) . The 1 H NMR spectrum of EPZ015564 is shown in Supplemental Figure 1 . All other reagents were purchased from sources as described below.
Pharmacokinetic Study in Rats.
All animal studies were performed in accordance with the AAALAC International and NIH were constructed by analyzing a series of control plasma, bile or urine aliquots containing 100 ng/mL dexamethasone as internal standard and 0.5 ng/mL (Group 1) or 2.0 ng/mL (Group 2) to 1000 ng/mL EPZ011652. Three levels of quality controls were also included in the analysis (1, 50 and 800 ng/mL for Group 1 and 3, 50 and 800 ng/mL for Group 2). The concentration of EPZ011652 in each unknown sample was determined by solving the linear calibration curve equation for each corresponding drug/internal standard ratio. Pharmacokinetic parameters were calculated by non-compartmental methods using Phoenix WinNonlin 6.2 (Certara, St-Louis, MO). Terminal half-life values were determined by regression of at least 3 data-points in the later phase of the time-concentration profile. Parameters are presented as mean ± SD were applicable. Parent excretion in urine or bile was calculated as the % dose excreted = sum of (urine or bile concentration * urine or bile volume), divided by dose.
Metabolite Identification in Rat Plasma and Bile.
Aliquots of individual rat plasma and bile (0 to 4 h time-points) were pooled for metabolite identification studies. The 0-4 h collection interval corresponded to 88% of the plasma AUC 0-inf and so was deemed representative of the overall metabolite profile. Plasma samples were
quenched with 1 volume of methanol followed by centrifugation 4°C (16100 g, 15 min). One volume of acetonitrile was added to bile samples prior to centrifugation. Metabolites were identified using a Q-TOF Premier exact mass spectrometer (Waters, Milford, MA).
Chromatography separation was performed using an ACUITY UPLC system with a binary solvent manager using 50 mM ammonium acetate in water (A) and 0.1% formic acid in acetonitrile (B) as the mobile phase with the following gradient: 0 to 24 min: gradient from 95%
A/5% B to 95% B at a flow rate of 400 μ L/min. The analytical column used was a Nucleodur C18 Gravity (5 µm, 2 x 50 mm; Macherey-Nagel, Bethlehem, PA). The injection volume was 10 µL. The mass spectrometer was operated with a desolvation temperature of 300°C, desolvation gas at 500 L/h, source temperature of 100°C, cone gas at 20 L/h and the spray capillary was set to 2.5 kV. A prescreening full scan from 50 to 950 amu (positive ion electrospray) was performed for comprehensive analysis of metabolites. The possible chemical structures of the metabolites were deduced based on their MS 1 and MS 2 spectra in addition to their exact mass.
Metabolite Profiling in Liver S9.
Following identification of M1 in rat bile, EPZ011652 was incubated with human and rat S9.
Male pooled human (10 donors) and Sprague-Dawley rat liver S9 were obtained (Bioreclamation IVT, Baltimore, MD). EPZ011652, 10 μM, was added to 100 mM phosphate buffer, pH 7. (1 mM) and were terminated by removing an aliquot of the incubation into methanol. Reaction times were 30 min for NAT1 and 15 min for NAT2. Standard curves were prepared in protein concentration matched control-insect cell cytosol to allow quantification of the rate of metabolite formation. Following centrifugation at 2500 rpm for 30 min at 4 o C to precipitate protein, the sample supernatants were diluted with deionised water containing internal standard prior to LC-MS/MS analysis using the method described above for NAT phenotyping.
Non-linear regression analysis of enzyme kinetic data was carried out using the enzyme kinetics module of SigmaPlot version 11.0 (Systat Software Inc. Chicago, IL), using models for the Hill clearance (CL) of 96.2 ± 16.3 mL/min/kg and 73.7 ± 13.6 mL/min/kg, respectively. Likewise, similar volumes of distribution at steady state (V ss ) were observed that were several-fold greater than total body water at 7.93 ± 1.44 L/kg and 8.10 ± 2.12 L/kg, respectively (Table 1) . AUC 0-t and AUC 0-inf , the areas under the curve to the last measurable data point and extrapolated to infinity, respectively, increased in a dose-proportional manner. Following 10 mg/kg iv administration, renal CL (1.51 ± 0.906 mL/min/kg) and biliary CL (0.050 ± 0.029 mL/min/kg) were minor pathways of excretion for EPZ011652, with only 8.29 ± 4.24% of the parent recovered in urine and less than 1% of the parent recovered in bile after 24 hours. Neither M2, M3 nor M4 were observed in human and rat liver S9 incubations and additionally no evidence of glucuronidation was seen in rat bile or in liver S9 fractions supplemented with UDPGA.
Identification of the Major Metabolites of EPZ011652 in

M1 (EPZ015564) Formation in Pooled Human, Rat and Dog Hepatocytes. EPZ011652
showed a high scaled clearance (59 mL/min/kg) in rat hepatocytes, correlating well with the rat in vivo clearance. A moderate scaled clearance in dog hepatocytes (15 mL/min/kg) and low clearance (<5 mL/min/kg) in human hepatocytes were also observed (Table 3) . Using EPZ015564, the synthesized authentic reference standard of M1, enabled the concentration of the metabolite to be monitored over time as summarized in Table 3 . In rats, EPZ015564
concentration declined with incubation time, with a peak level of 74 nM at 15 minutes, likely due to sequential metabolism, as was observed in vivo. In contrast, EPZ015564 was detected only after 45 minutes of incubation in human hepatocytes and increased with incubation time up to 9 nM at 120 min. EPZ015564 was not detected in dog hepatocyte incubations, in line with the absence of NAT positive control metabolites, p-acetamidobenzoic acid and N-acetyl sulfamethazine formation in this species.
Human NAT1 and NAT2 Phenotyping. Formation of EPZ015564 (M1) from incubations with
EPZ011652 was minimal in the presence of human NAT1, with a conversion of less than 1% of the initial parent concentration (3.1 nM EPZ015564 at 45 min). In contrast, p-aminobenzoic acid, a known NAT1 substrate had a half-life of less than 2 minutes under the same incubation conditions. EPZ011652 N-acetylation was much more extensive in the presence of NAT2 compared to NAT1, with more than 50% of the initial parent concentration converted to
EPZ015564 within 45 minutes (final concentration of 527 nM). Under similar incubation
This article has not been copyedited and formatted. The final version may differ from this version. in this species (Collins, 2001) . This was expected, as NATs are expressed in humans and rats, but not in dogs due to an absence of the NAT genes (Trepanier et al., 1997) , and suggests that NATs are the primary enzymes implicated in the formation of EPZ015564. The high intrinsic clearance of EPZ011652 in rat hepatocytes correlated well with the systemic clearance observed in an in vivo pharmacokinetic study and was roughly equivalent to hepatic blood flow. In contrast, the scaled clearance of the compound was moderate in dog hepatocytes and low (<5 mL/min/kg) in human hepatocytes. In rat hepatocytes, the concentration of EPZ015564 increased the liver and gut (Husain et al., 2007a (Husain et al., , 2007b . Similar findings have been noted for certain heterocyclic amines, with the N-acetylation of a piperazine moiety recently reported (Rawal et al., 2008) . UK-469,413 had good physicochemical properties and was slowly metabolized by CYP in rat and human liver microsomes. However, in rat in vivo the compound was highly cleared and subsequently shown to be rapidly acetylated in rat liver cytosol to an Nacetylpiperazine metabolite that was the major circulating metabolite in rat plasma in vivo. Using specific inhibitors, correlation analysis and expressed human NAT enzymes, the compound was shown to be a NAT2 substrate. The current study further adds to these observations that NAT isozymes have the capacity to N-acetylate substrates other than the classical arylamine and hydrazine motifs. The apparent K m of 165 µM observed with human NAT2 is in the same range as reported for sulfamethazine, an arylamine commonly used as a positive control for NAT2 acetylation (K m of 110 to 600 μM; Delomenie et al, 1997; Hickman et al., 1995; Meyer et al., 2014; Zang et al., 2007) and isoniazid, a well characterized hydrazine substrate (Hickman et al., 1995) . Thus, although N-acetylation of an aliphatic amine is an uncommon reaction, NAT2 affinity for EPZ011652 was in the same range as that reported for classical arylamine and hydrazine substrates such as sulfamethazine and isoniazid. It should also be noted that there are other enzymes capable of N-acetylation of aliphatic amines, in particular Spermidine/Spermine- The two NAT genes are 87% homologous and are located at 8p22, a chromosomal region commonly deleted in human cancers. The sequencing of NAT1 and NAT2 genes has revealed a number of allelic variants that affect activity of both genes in vivo, providing a genetic understanding for the long known functional polymorphism in NAT2 activity and, more recently, in NAT1 activity. This genetic variation modulates the acetylator status of individuals and therefore can impact their predisposition to toxicity and disease. Since the capacity of NAT2 varies in humans, manifest as rapid, intermediate and slow acetylator phenotypes (Hein, 2000) , N-acetylation as the major elimination pathway can lead to variability in exposure in humans.
This was the basis for the recent mechanistic work on the enzymology of etamicastat clearance, wherein high variability in etamicastat exposures in a rising, multiple dose study in healthy volunteers was associated with the polymorphic NAT2-mediated N-acetylation pathway (Nunes et al., 2010; Loureiro et al., 2013) . The extent of systemic exposure to etamicastat in NAT2 slow acetylators was 1.5-6.7 times higher than in NAT2 fast acetylators, whereas exposure to etamicastat N-acetyl metabolite was 1.5-3.5 times higher in rapid NAT2 acetylators, thus etamicastat pharmacokinetics were markedly affected by the NAT2 phenotype (Nunes et al., 2010) .
In addition to the clinical implications of this pathway, it has consequences for drug discovery and design. In our program, efforts were focused on perturbing this metabolic pathway and the N-acetylation reaction could be blocked by alkyl substituents on the terminal nitrogen, with the N-methyl analogs showing superior PK with retention of potency compared to EPZ011652 (Mitchell et al., 2015) . 
